ABTC 1501: A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM

Eligibility Checklist

Patient Name:

Last_____ First_____

Eligibility Criteria:

Q.1	Projected Start Date of Treatment	MM/DD/YYYY		
Q.2	Assigned Treatment Part	Part:		
Q.3	Does the patient have a histologically proven glioblastoma or gliosarcoma which is progressive or recurrent (per RANO criteria, Section 8.1) following radiation therapy and temozolomide?	YES	NO	
Q.4	Does the patient have available tumor MGMT methylation status? Results of routinely used methods for MGMT methylation testing (e.g. MSPCR or quantitative PCR) are acceptable.	YES	NO	
Q.5	Does the patient have measurable contrast-enhancing disease (defined as at least 1 cm x 1 cm x 1 cm) by MRI imaging within 21 days prior to starting treatment (patients may have gross total resection, but should have measurable disease post-operatively)?	YES	NO	
Q.6	Date of Baseline MRI	MM/DD/YYYY		
Q.7	Is the patient able to undergo MRI of the brain with gadolinium?	YES	NO	
Q.8	Was the patient maintained on a stable corticosteroid regimen for five days prior to the baseline MRI?	YES	NO	
Q.9	Is the patient in the first recurrence of glioblastoma following radiation therapy and temozolomide?	YES	NO	
Q.10	Has patient recovered from severe toxicity of prior therapy? An interval of at least 12 weeks must have elapsed since the completion of radiation therapy or placement of Gliadel wafers, and at least 6 weeks must have elapsed from the last dose of temozolomide (TMZ).	YES	NO	N/A
Q.11	Has the patient had any prior therapies other than radiation, temozolomide, and Gliadel wafers (placed during the first surgery at diagnosis of GBM)	NO	YES	
Q.12	Is the subject equal to or greater than 18 years of age?	YES	NO	
Q.13	Karnofsky Performance Status	KPS		
Q.14	Ability to provide written informed consent	YES	NO	
Q.15	If the patient is a woman of childbearing potential, has the patient agreed to have a negative serum pregnancy test within 24 hours prior to treatment start?	YES	NO	
Q.16	If the patient is a woman of childbearing potential, has the patient agreed to use two methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 23 weeks after the last dose of study drug?	YES	NO	N/A
Q.17	If the patient is a sexually active man of reproductive potential who are partners of women with reproductive potential, has the patient agreed to use two methods of contraception (hormonal or barrier method of birth control;	YES	NO	N/A

	abstinence) prior to study entry, for the duration of study treatment, and through at least 32 weeks after the last dose of study drug?			
Q.18	Does the patient have a concurrent malignancy other than curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder?	NO	YES	
Q.19	Has the patient had a prior malignancy within the past 5 years?	NO	YES	
Q.20	Is the patient receiving any other investigational agent?	NO	YES	
Q.21	Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biological composition to Anti-LAG-3, Anti-CD137, and Anti-PD1?	NO	YES	
Q.22	Does the patient have active or recent history of known or suspected autoimmune disease? Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, and skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll.	NO	YES	
Q.23	Does the patient have a concurrent condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study entry?	NO	YES	
Q.24	Has the patient been receiving greater than 1 mg dexamethasone/day (or an equivalent amount of an alternative corticosteroid) for at least 1 week prior to treatment start?	NO	YES	
Q.25	Does the patient have no evidence of significant mass effect, no midline shift, and no uncontrolled clinical signs of mass effect?	YES	NO	
Q.26	Does the patient have no evidence of significant hematologic, renal, or hepatic dysfunction?	YES	NO	
Q.27	Does the patient have a history of any chronic hepatitis as evidenced by the following: positive test for hepatitis B surface antigen (HBsAg), positive test for qualitative hepatitis C viral load (by PCR) (Note: Subjects with positive hepatitis C antibody and negative quantitative hepatitis C by PCR are eligible. History of resolved hepatitis A virus infection is not an exclusion criterion.), history of alcoholic or non-alcoholic steatohepatitis (NASH), auto-immune hepatitis, or previous grade 3-4 drug-related hepatitis, or any form of chronic-liver disease?	NO	YES	
Q.28	Is the patient HCV negative (by qPCR) and HBcAb negative (no prior Hepatitis B infection)?	YES	NO	
Q.29	Does the patient have a confirmed history of encephalitis, meningitis, or uncontrolled seizures within the year prior to signing informed consent?	NO	YES	
Q.30	Does the patient have uncontrolled or significant cardiovascular disease including, but not limited to: myocardial infarction or stroke/transient ischemic attack (TIA) within the 6 months prior to consent, uncontrolled angina with the 3 months prior to consent, any history or clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes),	NO	YES	

	QTc prolongation > 480 msec, history of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant coronary stent occlusion, deep venous thrombosis, etc.), or cardiovascular disease-related requirement for daily supplemental oxygen.			
Q.31	Does the patient have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirement?	NO	YES	
Q.32	Has patient agreed to stop breastfeeding?	YES	NO	
Q.33	Is the patient HIV-positive on combination antiretroviral therapy?	NO	YES	
Q.34	Does the patient have Gilbert's Syndrome?	NO	YES	

Laboratory Eligibility Criteria:

Lab Test	Sample Collection Date	Lab Value	Unit of Measure	Lower Limit Normal	Upper Limit Normal
Absolute Lymphocyte Count			{Cells}/ µL	N/A	N/A
Absolute Neutrophil Count			{Cells}/µL	N/A	N/A
Platelets			/µL	N/A	N/A
Hemoglobin			g/dL	N/A	N/A
Serum Total Bilirubin			mg/dL		
Direct Bilirubin			mg/dL	N/A	
Aspartate Aminotransferase, Serum			u/L		
Alanine Aminotransferase, Serum			u/L		
Serum Creatinine			mg/dL		
Creatinine Clearance			ml/min/1.73m^2	60	N/A
Partial Prothromboplastin Time			sec		
Activated Partial Prothromboplastin Time			sec		